In a previous work, we showed that artificially modulating O-GlcNAcylation levels in colon cancer cells, led to compensatory adjustments in OGT and OGA in an attempt to restore basal O-GlcNAcylation levels [33]. The gene discussed is OGA; the disease is malignant colon neoplasm.